Clinical-stage oncology company Black Diamond Therapeutics Inc. (BDTX) is advancing with growing visibility in biotech circles following a series of clinical and strategic updates tied to its lead candidate, silevertinib (BDTX-1535).
The company recently announced the completion of enrollment for its Phase 2 trial evaluating silevertinib in first-line (1L) patients with non-classical EGFR-mutant non-small cell lung cancer (NSCLC). A total of 43 patients have been enrolled, and data on objective response rate (ORR) and preliminary duration of response (DOR) are expected to be released in the fourth quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.